KR930702015A - 각막 장해 치료제 - Google Patents

각막 장해 치료제

Info

Publication number
KR930702015A
KR930702015A KR1019930700610A KR930700610A KR930702015A KR 930702015 A KR930702015 A KR 930702015A KR 1019930700610 A KR1019930700610 A KR 1019930700610A KR 930700610 A KR930700610 A KR 930700610A KR 930702015 A KR930702015 A KR 930702015A
Authority
KR
South Korea
Prior art keywords
corneal
interleukin
corneal disorder
agent
remedy
Prior art date
Application number
KR1019930700610A
Other languages
English (en)
Other versions
KR960002739B1 (ko
Inventor
데루오 니시다
Original Assignee
데루오 니시다
모리따 다까까스
산뗑세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데루오 니시다, 모리따 다까까스, 산뗑세이야꾸 가부시끼가이샤 filed Critical 데루오 니시다
Publication of KR930702015A publication Critical patent/KR930702015A/ko
Application granted granted Critical
Publication of KR960002739B1 publication Critical patent/KR960002739B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 인터루킨-6을 유효 성분으로 하고, 각막 궤양, 각막 상피 박리, 각막염, 인구 건조증 등 여러가지의 요인으로 손상을 받음으로써 생기는 각막 장해에 대한 치료제에 관한 것이다.

Description

각막 장해 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 인터루킨-6을 유효성분으로 하는 각막 장해 치료제.
  2. 인터루킨-6을 사용하는 각막 장해의 치료방법.
  3. 인터루킨-6과 의약으로서 허용되는 첨가물로 이루어진 제제를 투여하는 것을 특징으로 하는 각막 장해의 치료방법.
  4. 인터루킨-6과 의약으로서 허용되는 첨가물로 이루어진 제제를 점안 투여하는 것을 특징으로 하는 각막 장해의 치료방법.
  5. 각막 장해의 치료에 사용하는 인터루킨-6.
  6. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930700610A 1990-08-31 1991-08-27 각막 장해 치료제 KR960002739B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP90231954 1990-08-31
JP90-231954 1990-08-31
JP23195490 1990-08-31
PCT/JP1991/001130 WO1992004041A1 (en) 1990-08-31 1991-08-27 Remedy for corneal damages

Publications (2)

Publication Number Publication Date
KR930702015A true KR930702015A (ko) 1993-09-08
KR960002739B1 KR960002739B1 (ko) 1996-02-26

Family

ID=16931665

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930700610A KR960002739B1 (ko) 1990-08-31 1991-08-27 각막 장해 치료제

Country Status (7)

Country Link
US (1) US5433944A (ko)
EP (1) EP0547223B1 (ko)
JP (1) JP2534176B2 (ko)
KR (1) KR960002739B1 (ko)
DE (1) DE69122764T2 (ko)
DK (1) DK0547223T3 (ko)
WO (1) WO1992004041A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
JP2676341B2 (ja) * 1986-12-18 1997-11-12 味の素株式会社 Ｂ細胞分化因子の製造法
JP2583248B2 (ja) * 1987-05-13 1997-02-19 味の素株式会社 免疫療法剤
JPH04500208A (ja) * 1988-08-26 1992-01-16 シェリング・コーポレーション インターロイキン―６で末端分化を誘導することによる骨髄性白血病の治療
JPH037585A (ja) * 1989-01-20 1991-01-14 Univ Yale 光活性オリゴヌクレオチドによる遺伝子発現の選択的阻害
JP2930362B2 (ja) * 1990-04-09 1999-08-03 東ソー株式会社 感作ｔ細胞関与疾患の治療剤
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
JP3007585U (ja) 1994-05-13 1995-02-21 株式会社横浜プラスチック 気密性をよくした容器

Also Published As

Publication number Publication date
DE69122764T2 (de) 1997-03-20
DK0547223T3 (da) 1997-02-10
EP0547223A4 (en) 1993-10-13
EP0547223A1 (en) 1993-06-23
US5433944A (en) 1995-07-18
WO1992004041A1 (en) 1992-03-19
DE69122764D1 (de) 1996-11-21
KR960002739B1 (ko) 1996-02-26
EP0547223B1 (en) 1996-10-16
JP2534176B2 (ja) 1996-09-11

Similar Documents

Publication Publication Date Title
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
KR890011590A (ko) 안지오스타틴
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
FI963871A0 (fi) Farmaseuttinen formulointi tekijän VIII tai tekijän IX antamiseksi ihonalaisesti, lihaksensisäisesti tai ihonsisäisesti
LV10924A (lv) Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ES2166436T3 (es) Protector oftalmico biodesgastable.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
KR920703041A (ko) 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
KR920016088A (ko) 하부 요로 질환의 치료
ES2063998T3 (es) Uso de esteres de acidos n-alquil 1,4-dihidropiridin-dicarboxilicos como medicamentos, nuevos compuestos y procedimiento para su preparacion.
KR930702015A (ko) 각막 장해 치료제
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
KR910019623A (ko) 상승병용을 이용한 안고혈압 치료
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
DE3875349D1 (de) Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie.
Kellogg et al. Spinal conditioning in dogs
DE69837622D1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
KR910019622A (ko) 안과용 상승적 병용으로 안고혈압의 치료
IT8349538A0 (it) Esteri di derivati 3-(3-sostituitoammino-2-idrossi-propossi)-4-sostituito-1,2,5-tiadiazolici utili come agenti bloccanti beta-adrenergici eper il trattamento del glaucoma
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020220

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee